443 related articles for article (PubMed ID: 16954387)
1. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.
Sharma VM; Calvo JA; Draheim KM; Cunningham LA; Hermance N; Beverly L; Krishnamoorthy V; Bhasin M; Capobianco AJ; Kelliher MA
Mol Cell Biol; 2006 Nov; 26(21):8022-31. PubMed ID: 16954387
[TBL] [Abstract][Full Text] [Related]
2. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth.
Palomero T; Lim WK; Odom DT; Sulis ML; Real PJ; Margolin A; Barnes KC; O'Neil J; Neuberg D; Weng AP; Aster JC; Sigaux F; Soulier J; Look AT; Young RA; Califano A; Ferrando AA
Proc Natl Acad Sci U S A; 2006 Nov; 103(48):18261-6. PubMed ID: 17114293
[TBL] [Abstract][Full Text] [Related]
3. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.
Thompson BJ; Buonamici S; Sulis ML; Palomero T; Vilimas T; Basso G; Ferrando A; Aifantis I
J Exp Med; 2007 Aug; 204(8):1825-35. PubMed ID: 17646408
[TBL] [Abstract][Full Text] [Related]
4. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
[TBL] [Abstract][Full Text] [Related]
5. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
6. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.
Palomero T; Barnes KC; Real PJ; Glade Bender JL; Sulis ML; Murty VV; Colovai AI; Balbin M; Ferrando AA
Leukemia; 2006 Jul; 20(7):1279-87. PubMed ID: 16688224
[TBL] [Abstract][Full Text] [Related]
7. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
8. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
9. The Notch1/c-Myc pathway in T cell leukemia.
Sharma VM; Draheim KM; Kelliher MA
Cell Cycle; 2007 Apr; 6(8):927-30. PubMed ID: 17404512
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
[TBL] [Abstract][Full Text] [Related]
11. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1.
Li X; Gounari F; Protopopov A; Khazaie K; von Boehmer H
J Exp Med; 2008 Nov; 205(12):2851-61. PubMed ID: 18981238
[TBL] [Abstract][Full Text] [Related]
12. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
13. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma.
Weng AP; Millholland JM; Yashiro-Ohtani Y; Arcangeli ML; Lau A; Wai C; Del Bianco C; Rodriguez CG; Sai H; Tobias J; Li Y; Wolfe MS; Shachaf C; Felsher D; Blacklow SC; Pear WS; Aster JC
Genes Dev; 2006 Aug; 20(15):2096-109. PubMed ID: 16847353
[TBL] [Abstract][Full Text] [Related]
14. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
15. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice.
Klinakis A; Szabolcs M; Politi K; Kiaris H; Artavanis-Tsakonas S; Efstratiadis A
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9262-7. PubMed ID: 16751266
[TBL] [Abstract][Full Text] [Related]
16. Activating Notch1 mutations in mouse models of T-ALL.
O'Neil J; Calvo J; McKenna K; Krishnamoorthy V; Aster JC; Bassing CH; Alt FW; Kelliher M; Look AT
Blood; 2006 Jan; 107(2):781-5. PubMed ID: 16166587
[TBL] [Abstract][Full Text] [Related]
17. Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development.
Wang Q; Yan R; Pinnell N; McCarter AC; Oh Y; Liu Y; Sha C; Garber NF; Chen Y; Wu Q; Ku CJ; Tran I; Serna Alarcon A; Kuick R; Engel JD; Maillard I; Cierpicki T; Chiang MY
Blood; 2018 Sep; 132(12):1279-1292. PubMed ID: 30076146
[TBL] [Abstract][Full Text] [Related]
18. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
19. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752.
Chen X; Gong L; Ou R; Zheng Z; Chen J; Xie F; Huang X; Qiu J; Zhang W; Jiang Q; Yang Y; Zhu H; Shi Z; Yan X
Gynecol Oncol; 2016 Mar; 140(3):537-44. PubMed ID: 26704638
[TBL] [Abstract][Full Text] [Related]
20. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
Sanchez-Martin M; Ferrando A
Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
